MedTrace Logo

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

NCT01657981 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2013-06-26

No results posted yet for this study

Summary

The study aims to observe how YM150 was absorbed, distributed and excreted after dosing with a radio labeled drinking solution.

Conditions

  • Pharmacokinetics
  • Healthy Male Subjects

Interventions

DRUG

YM150

14C-labeled YM150, oral solution

Sponsors & Collaborators

  • Astellas Pharma Europe B.V.

    lead INDUSTRY

Principal Investigators

  • Clinical Study Manager · Astellas Pharma Europe B.V.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01657981 on ClinicalTrials.gov